交银国际表示，近期医药板块在大幅震荡后小幅回升，考虑到板块估值仍处于历史底部、叠加后续宏观利好政策出台+流动性改善，该行认为仍有进一步修复空间。继续重点推荐医保谈判潜在受益标的，包括康方生物、先声药业、传奇生物、云顶新耀、和黄医药等短期催化剂丰富、盈利高增长或盈亏平衡时间点明确、估值有较大修复弹性的创新药标的。Some pharmaceutical stocks rose, as of the time of publication, Kejie Pharmaceutical -B (02171) rose by 33.68% to HK$8.97; Conceragen Pharmaceuticals -B (09966) rose by 10.34% to HK$4.27; Lepu Biomedical -B (02157) rose by 7.87% to HK$3.29.
According to the Securities Times app, some pharmaceutical stocks rose, as of the time of publication, Kejie Pharmaceutical -B (02171) rose by 33.68% to HK$8.97; Conceragen Pharmaceuticals -B (09966) rose by 10.34% to HK$4.27; Lepu Biomedical -B (02157) rose by 7.87% to HK$3.29; Cloud Top Newshine -B (01952) rose by 6.77% to HK$34.7; Yiming Angke -B (01541) rose by 3.42% to HK$7.55.
On the news front, according to the National Medical Insurance Administration, the on-site negotiations for the adjustment of the national medical insurance drug list for 2024 have been successfully completed. The expanded new version of the medical insurance drug list is expected to be officially released to the public at the end of November and will be implemented from January 1, 2025. Ping An Securities pointed out that in addition to this negotiation, focusing on "accelerating the clinical application of innovative drugs" highlights the innovative value of products. Southwest Securities stated that negotiations on innovative drugs at a national level and the landing of the third quarter report. The direction of investment opportunities for negotiations on innovative drugs at a national level is worth looking forward to.
Bocom International stated that recently, the pharmaceutical sector has seen a slight rebound after significant volatility. Considering that the sector's valuation is still at historical lows, coupled with the subsequent positive macroeconomic policies + improved liquidity, the bank believes there is still room for further recovery. They continue to focus on recommending potential beneficiaries of medical insurance negotiations, including Akeso, Simcere Pharma, Legend Biotech, Cloud Top Newshine, and Hutchmed (China), which are innovative drug symbols with rich short-term catalysts, high profit growth or clear profit/loss balance points, and valuation with significant repair elasticity.
